Article
Psychiatry
Orly Lipsitz, Roger S. McIntyre, Nelson B. Rodrigues, Yena Lee, Danielle S. Cha, Hartej Gill, Mehala Subramaniapillai, Kevin Kratiuk, Kangguang Lin, Roger Ho, Rodrigo B. Mansur, Joshua D. Rosenblat
Summary: The study found that menopausal status does not influence the overall treatment response of women with TRD receiving IV ketamine. Both premenopausal and postmenopausal participants showed similar response rates and remission rates to IV ketamine treatment following four infusions, but premenopausal women experienced improvements in social function more rapidly, while postmenopausal women experienced reduction in suicidal ideation more rapidly.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)
Article
Clinical Neurology
Fabrice Jollant, Christophe Demattei, Pascale Fabbro, Mocrane Abbar
Summary: Ketamine is effective in reducing suicidal thoughts in the short term for suicidal patients. Clinical factors poorly predict remission, and fluctuations in suicidal ideas necessitate vigilance and multimodal care. Remission after the first infusion is highly predictive of future remission.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Orly Lipsitz, Roger S. McIntyre, Nelson B. Rodrigues, Tyler S. Kaster, Danielle S. Cha, Elisa Brietzke, Hartej Gill, Flora Nasri, Kangguang Lin, Mehala Subramaniapillai, Kevin Kratiuk, Kayla Teopiz, Leanna M. W. Lui, Yena Lee, Roger Ho, Margarita Shekotikhina, Rodrigo B. Mansur, Joshua D. Rosenblat
Summary: Early improvement with IV ketamine treatment predicts treatment response in depression patients. Even without early improvements, patients may still experience significant symptom reduction after four infusions.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Psychiatry
Nelson B. Rodrigues, Roger S. McIntyre, Orly Lipsitz, Yena Lee, Mehala Subramaniapillai, Kevin Kratiuk, Amna Majeed, Flora Nasri, Hartej Gill, Rodrigo B. Mansur, Joshua D. Rosenblat
Summary: The study found that intravenous ketamine significantly reduced workplace/school disability, improved work efficiency, and decreased absenteeism in patients with treatment-resistant depression, demonstrating sustained antidepressant effects.
PSYCHIATRY RESEARCH
(2021)
Article
Psychiatry
Roger S. McIntyre, Joshua D. Rosenblat, Nelson B. Rodrigues, Orly Lipsitz, David Chen-Li, Jung Goo Lee, Flora Nasri, Mehala Subramaniapillai, Kevin Kratiuk, Andrew Wang, Hartej Gill, Rodrigo B. Mansur, Roger Ho, Kangguang Lin, Yena Lee
Summary: The study found that intravenous ketamine can significantly improve cognitive function in TRD patients, especially in tests like DSST and PDQ-5-D. This improvement is mainly mediated by reduced depressive symptoms, indicating that ketamine has independent and rapid effects in promoting cognition.
PSYCHIATRY RESEARCH
(2021)
Review
Public, Environmental & Occupational Health
Annabella Hochschild, Michael F. Grunebaum, J. John Mann
Summary: Suicide rates have been increasing for close to twenty years in many countries, with most attempts and deaths associated with psychiatric illness, typically depression. Subanesthetic ketamine, the only FDA-approved antidepressant that works rapidly, may reduce suicidal ideation in depressed patients, but further research is needed on dosing strategy and long-term efficacy.
PREVENTIVE MEDICINE
(2021)
Article
Neurosciences
Wei Zheng, Limei Gu, Yanling Zhou, Chengyu Wang, Xiaofeng Lan, Bin Zhang, Zezhi Li, Yuping Ning
Summary: This study investigated the relationship between plasma BDNF levels and the effects of repeated-dose intravenous ketamine on anhedonic symptoms in individuals with MDD. The results showed that baseline pBDNF concentrations may predict the antianhedonic effect of ketamine.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Clinical Neurology
Nelson B. Rodrigues, Roger S. McIntyre, Orly Lipsitz, Danielle S. Cha, Bing Cao, Yena Lee, Hartej Gill, Leanna M. W. Lui, Wieslaw Cubala, Roger Ho, Margarita Shekotikhina, Kayla M. Teopiz, Mehala Subramaniapillai, Kevin Kratiuk, Rodrigo B. Mansur, Joshua D. Rosenblat
Summary: Changes in sleep symptoms are closely related to the anti-depressive and anti-suicidal effects of IV ketamine in patients with treatment-resistant depression, with improvements in sleep playing a crucial role in alleviating disease severity.
JOURNAL OF SLEEP RESEARCH
(2022)
Article
Psychiatry
Yanling Zhou, Chengyu Wang, Xiaofeng Lan, Weicheng Li, Ziyuan Chao, Kai Wu, Roger S. McIntyre, Yuping Ning
Summary: This study demonstrates that ketamine treatment can improve suicidal ideation, and this improvement is partially mediated by the enhancement of cognitive function.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Immunology
Shunjie Bai, Liang Fang, Jing Xie, Huili Bai, Wei Wang, Jian-jun Chen
Summary: This study identified four potential biomarkers, including AAT, TRSF, HDLC, and APOA1, for diagnosing MDD patients with suicidal ideation. Levels of AAT and APOA1 significantly improved after treatment, with the biomarker panel showing excellent diagnostic performance.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Clinical Neurology
Maya Kuperberg, Douglas Katz, Sophie L. A. Greenebaum, Nevita George, Louisa G. Sylvia, Gustavo Kinrys, Astrid Desrosiers, Andrew A. Nierenberg
Summary: This study examined the relationship between psychotic symptoms during bipolar depressive episodes and suicidal ideation among outpatients with bipolar disorder. The results indicated that patients with psychotic symptoms were more likely to report active suicidal thoughts, including specific plans and methods.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
Roger S. McIntyre, Nelson B. Rodrigues, Orly Lipsitz, Flora Nasri, Hartej Gill, Leanna M. W. Lui, Mehala Subramaniapillai, Kevin Kratiuk, Kayla Teopiz, Roger Ho, Yena Lee, Rodrigo B. Mansur, Joshua D. Rosenblat
Summary: The study demonstrates that individuals meeting criteria for anxious-distress exhibited a greater reduction in symptoms after receiving IV ketamine treatment, with both high-anxiety and low-anxiety patients showing significant reductions in suicidal ideation after four infusions. Additionally, the anxious-distress group showed a more significant reduction in anxiety symptoms compared to the non-anxious distress group after three and four infusions.
JOURNAL OF PSYCHOPHARMACOLOGY
(2021)
Review
Clinical Neurology
Cheng-Chuan Chen, Na Zhou, Na Hu, Jian-Guo Feng, Xiao-Bin Wang
Summary: This meta-analysis found that intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine have significant anti-suicidal ideation effects. Specifically, ketamine produced a large anti-suicidal ideation effect within 4-6 hours and a medium-large effect within 24 hours. Esketamine, on the other hand, produced a small-medium anti-suicidal ideation effect within the 4-6 hours timeframe and the 24 hours.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Article
Clinical Neurology
Jess G. Fiedorowicz, Jane E. Persons, Shervin Assari, Michael J. Ostacher, Fernando S. Goes, John Nurnberger, William H. Coryell
Summary: Depressive symptoms are strongly linked to suicidal ideation and behavior, serving as important risk factors for suicide. However, manic symptoms show no clear association with suicide risk, and mixed symptoms do not convey a greater risk of suicidal ideation or behavior than depressive symptoms alone.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
Xiaoyu Chen, Mingqia Wang, Yiru Hu, Yanni Zhan, Yanling Zhou, Wei Zheng, Weijian Liu, Chengyu Wang, Xiaomei Zhong, Hanqiu Li, Xiaofeng Lan, Yuping Ning, Bin Zhang
Summary: The study found that in MDD patients, ketamine treatment significantly improved working memory, and this improvement was associated with alleviation of depressive symptoms and reduction in suicidal ideation. Furthermore, the improvement in working memory may predict the anti-suicidal ideation response of ketamine.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
(2021)
Review
Clinical Neurology
Roger S. Mcintyre, Leslie Citrome, Hannah Cummings, Mark S. Todtenkopf, Laura A. Tan, Marni White, Sarah Akerman
Summary: The endogenous opioid system plays an important role in weight and metabolism regulation. Targeting this system may help mitigate antipsychotic-induced weight gain and metabolic dysregulation.
Review
Clinical Neurology
Oloruntoba J. Oluboka, Martin A. Katzman, Jeffrey Habert, Atul Khullar, Margaret A. Oakander, Diane McIntosh, Roger S. McIntyre, Claudio N. Soares, Raymond W. Lam, Larry J. Klassen, Robert Tanguay
Summary: Major depressive disorder (MDD) is the leading cause of disability worldwide, and comorbid chronic pain exacerbates disability and healthcare burden. Managing patients with both MDD and chronic pain can be challenging due to shared underlying mechanisms. Current treatment guidelines address comorbid conditions such as anxiety and cardiovascular disease, but not chronic pain. Rapidly and aggressively treating depression according to guideline recommendations, using antidepressants with analgesic properties, while also addressing pain, is recommended based on clinical experience.
Article
Clinical Neurology
Roger S. McIntyre, David G. Daniel, Eduard Vieta, Istvan Laszlovszky, Pascal J. Goetghebeur, Willie R. Earley, Mehul D. Patel
Summary: Post hoc analyses suggest that cariprazine may have potential benefits in improving cognitive symptoms in patients with bipolar I disorder and schizophrenia.
Review
Psychiatry
Smadar V. Tourjman, Gabriella Buck, Didier Jutras-Aswad, Atul Khullar, Shane McInerney, Gayatri Saraf, Jairo V. Pinto, Stephane Potvin, Marie-Josee Poulin, Benicio N. Frey, Sidney H. Kennedy, Raymond W. Lam, Glenda MacQueen, Roumen Milev, Sagar V. Parikh, Arun Ravindran, Roger S. McIntyre, Ayal Schaffer, Valerie H. Taylor, Michael van Ameringen, Lakshmi N. Yatham, Serge Beaulieu
Summary: This task force report examines the association between cannabis use and bipolar disorder, major depressive disorder, and comorbid cannabis use disorder. The results indicate that cannabis use is associated with worsened course and functioning of both mood disorders, particularly in bipolar disorder. However, the treatment of comorbid cannabis use disorder and major depressive disorder did not show significant results.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2023)
Article
Clinical Neurology
William S. H. Kim, Mikaela K. Dimick, Danielle Omrin, Rachel H. B. Mitchell, Daniel Riegert, Anthony Levitt, Ayal Schaffer, Susan Belo, John Iazzetta, Garfield Detzler, Mabel Choi, Stephen Choi, Nathan Herrmann, Roger S. McIntyre, Bradley J. MacIntosh, Beverley A. Orser, Benjamin I. Goldstein
Summary: A study found that an anesthetic gas containing nitrous oxide can significantly reduce depression severity in patients with bipolar disorder. Patients who used nitrous oxide had greater reductions in depression severity on the same day compared to the placebo group. Baseline cerebral blood flow predicted the decrease in depression severity with nitrous oxide, but not with midazolam. The findings suggest differential associations of nitrous oxide versus midazolam with bipolar depression severity and cerebral hemodynamics.
Article
Clinical Neurology
Farhan Fancy, Nelson B. Rodrigues, Joshua D. Di Vincenzo, Edmond H. Chau, Rickinder Sethi, Muhammad I. Husain, Hartej Gill, Aniqa Tabassum, Andrea Mckenzie, Lee Phan, Roger S. McIntyre, Joshua D. Rosenblat
Summary: This study observed the real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. Results showed that ketamine significantly reduced depressive symptoms, suicidal thoughts, and anxiety, while improving functioning. The more infusions received, the more significant the reduction in symptoms.
Article
Clinical Neurology
Houman Rashidian, Mehala Subramaniapillai, Caroline Park, Orly Lipsitz, Hannah Zuckerman, Bing Cao, Yena Lee, Hartej Gill, Roger Nelson Rodrigues, Joshua D. Di Vincenzo, Michelle Iacobucci, Saja Jaberi, Joshua D. Rosenblat, Roger S. McIntyre, Rodrigo B. Mansur
Summary: This study assessed changes in insulin resistance (IR) after antidepressant treatment and found that exacerbation of IR mediated non-response to treatment. In contrast, responders showed a reduction in IR. These findings further elucidate the role of IR in antidepressant response.
JOURNAL OF PSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Christoph U. Correll, Marco Solmi, Samuele Cortese, Maurizio Fava, Mikkel Hojlund, Helena C. Kraemer, Roger S. McIntyre, Daniel S. Pine, Lon S. Schneider, John M. Kane
Summary: Despite progress in pharmacotherapy, many mental disorders remain insufficiently treated due to limited knowledge of pathophysiology, lack of biological markers, and challenges in drug development and testing. This paper discusses promising drugs and innovative mechanisms of action undergoing testing for various psychiatric disorders, as well as the clinical trial parameters that need to be considered for successful drug development. It also highlights the hurdles and perils in new drug development and testing and emphasizes the importance of considering these factors for increased chances of success.
Article
Environmental Sciences
Yuxiao Zhao, Yueying Zhang, Kayla M. Teopiz, Leanna M. W. Lui, Roger S. McIntyre, Bing Cao
Summary: This study investigated the association between depression, vascular diseases (hypertension, myocardial infarction, stroke), diabetes mellitus, and functional impairment in middle-aged and elderly Chinese people. The results showed that depression was associated with functional decline in individuals with vascular disease/diabetes mellitus, highlighting the importance of treating depression in addition to managing vascular diseases.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2023)
Article
Clinical Neurology
Yanzhi Li, Lu Cheng, Lan Guo, Liwan Zhu, Hao Zhao, Caiyun Zhang, Manjun Shen, Yifeng Liu, Muhammad Youshay Jawad, Lingjiang Li, Wanxin Wang, Ciyong Lu, Roger S. McIntyre
Summary: This study explores the mediating role of personality traits in the relationship between adverse childhood experiences (ACEs) and depressive symptoms in older adults. The results suggest that maltreatment and household dysfunction induce depressive symptoms by increasing neuroticism, while poor parent-child bonding induces depressive symptoms by increasing neuroticism and reducing conscientiousness and extraversion.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Psychiatry
Michael E. Thase, Zahinoor Ismail, Stine R. Meehan, Catherine Weiss, Stephane Alexandre Regnier, Klaus Groes Larsen, Roger S. McIntyre
Summary: In this study, a subset of 10 items from the IDS-SR was identified that can measure life engagement in MDD. Different approaches, including expert selection, patient interviews, and PCA, consistently identified these items. These findings suggest the potential for creating an IDS-SR life engagement subscale.
JOURNAL OF PSYCHIATRIC RESEARCH
(2023)
Review
Nutrition & Dietetics
Joshua Daniel Di Vincenzo, Liam O'Brien, Ira Jacobs, Muhammad Youshay Jawad, Felicia Ceban, Shakila Meshkat, Hartej Gill, Aniqa Tabassum, Lee Phan, Sebastian Badulescu, Joshua Daniel Rosenblat, Roger S. McIntyre, Rodrigo B. Mansur
Summary: Psychiatric and metabolic disorders have a bidirectional relationship, yet the mechanisms underlying this association are unknown. This review explores the use of indirect calorimetry (IC) to assess resting metabolism in psychiatric populations and reveals significant differences in energy expenditure and substrate utilization compared to healthy populations. Predictive equations for resting energy expenditure in psychiatric populations tend to overestimate values, highlighting the need for standardized IC protocols and further research into the heterogeneity of psychiatric disorders.
Review
Neurosciences
Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni, Ziji Guo, Joshua D. Di Vincenzo, Giacomo d'Andrea, Aniqa Tabassum, Andrea Mckenzie, Sebastian Badulescu, Iria Grande, Roger S. McIntyre
Summary: The scoping review synthesized the current literature on the use of ketamine in bipolar depression. The preliminary evidence suggests that ketamine is a promising treatment with minimal risk and some effectiveness. Future studies should focus on ketamine's role in acute and maintenance treatment phases, as well as its effects on recurrence prevention and anti-suicidal measures.
Article
Neurosciences
Joanna K. Szmyd, Karol Lewczuk, Kayla M. Teopiz, Roger S. McIntyre, Adam Wichniak
Summary: This pilot study assessed patients' cognitive functioning with the Polish version of the THINC-it tool and analyzed its association with self-reported quality of life. The results suggest that the THINC-it tool has utility as a cognitive measure in adults with schizophrenia in both clinical and research settings.
Review
Psychiatry
Sipan Haikazian, David C. J. Chen-Li, Danica E. Johnson, Farhan Fancy, Anastasia Levinta, M. Ishrat Husain, Rodrigo B. Mansur, Roger S. McIntyre, Joshua D. Rosenblat
Summary: This review aimed to investigate the effect of psilocybin on depressive symptoms in patients with life-threatening illnesses or major depressive disorder. The results showed that psilocybin was effective in reducing depressive symptoms, with a large effect size. Further studies are needed to evaluate safety, efficacy, and treatment protocols.
PSYCHIATRY RESEARCH
(2023)
Article
Clinical Neurology
Jai Carmichael, Jennie Ponsford, Kate Rachel Gould, Gershon Spitz
Summary: The traditional approaches to measuring depression after traumatic brain injury (TBI) have limitations. This study adopted a symptom-oriented approach and found that post-TBI depression is highly heterogeneous. Different depressive symptoms have distinct associations with personal, injury-related, treatment, and outcome factors.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Xiaoning Sun, Min Chen, Guanghai Wang, Fan Jiang
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Aleksander Kwas
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Josine E. Verhoeven, Laura K. M. Han, Brenda W. J. H. Penninx
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Review
Clinical Neurology
Erin Crowe, Petra K. Staiger, Steven J. Bowe, Imogen Rehm, Richard Moulding, Caitlyn Herrick, David J. Hallford
Summary: This study aimed to integrate the evidence regarding the relationship between emotion regulation difficulties and TTM symptoms, and found that individuals with higher levels of TTM severity appear to exhibit decreased overall emotion regulation abilities and strategies.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Fjolla Berisha, Marjolaine Rivest-Beauregard, Jai Shah, Michelle Lonergan, Alain Brunet
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Yi-Tseng Tsai, Tzu-Jung Chuang, Sriyani Padmalatha Konara Mudiyanselage, Han-Chang Ku, Yi-Lin Wu, Chung-Yi Li, Nai-Ying Ko
Summary: Sleep disturbances are associated with higher suicide rates, and this association is independent of depression. Paying attention to sleep disturbances among PLHIV is crucial when monitoring suicidal ideation.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Junyou Chen, Ingrid D. Lui, Yu Cheng Hsu, Paul S. F. Yip
Summary: Despite rapid social changes in Hong Kong, marriage remains a strong protective factor against suicide for both men and women, particularly among younger individuals. Increasing suicide rates among divorced/separated, never-married, or widowed individuals suggest a need for more psychosocial support.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
A. Perry, K. Gordon-Smith, K. J. S. Lewis, A. Di Florio, N. Craddock, L. Jones, I. Jones
Summary: This study found that the experience of losing at least one night of sleep was associated with an increased risk of postpartum psychosis in women with bipolar disorder. Sleep quality in late pregnancy was not associated with postpartum psychosis, and perinatal sleep disruption was not associated with postpartum depression.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Dear J. Affect Disord, Mark J. Niciu, Robert C. Meisner, Brent R. Carr, Ali A. Farooqui, David Feifel, Adam Kaplin, Paul M. Kim, Christopher D. Schneck, Jennifer L. Vande Voort, Sagar Parikh, E. Jeremy Kendrick
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Tao Wang, Li Yang, Lan Yang, Bao-Peng Liu, Cun-Xian Jia
Summary: This study systematically reviewed the association between psychological pain and suicidality in patients with major depressive disorder (MDD). The results showed that psychological pain was a risk factor for suicidality in MDD patients, especially for those of advancing age. Reducing psychological pain in MDD patients is important for preventing suicidality.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Letter
Clinical Neurology
Juan Carlos Hugues, Abel Nogueira-Lopeza, Maeva Flayellea, Cora von Hammersteind, Joel Billieuxa
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Ogechi Cynthia Onyeka, Samuel D. Spencer, Alison Salloum, Katie Jiannetto, Eric A. Storch
Summary: This study examined the relationship among family accommodation (FA), posttraumatic stress symptoms (PTSS), and functional impairment. The results showed that FA was significantly associated with PTSS and functional impairment. Baseline FA partially mediated the relationship between baseline PTSS and functional impairment. Changes in FA from pre- to post-treatment were associated with relevant outcome variables at post-treatment and 12-month follow-up.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Yumeng Shi, Chao Yu
Summary: This study found a negative correlation between the intake of active microbes in the diet and depression.
JOURNAL OF AFFECTIVE DISORDERS
(2024)
Article
Clinical Neurology
Qiurui Nie, Yu Shen, Mengqin Luo, Zhiyong Sheng, Rui Zhou, Guangmin Li, Wei Huang, Shenjian Chen
Summary: The study assessed the sleep duration, sleep disorders, and trouble sleeping among adults in the United States from 2005 to 2018, revealing a high prevalence of abnormal sleep durations and increasing rates of sleep disorders and trouble sleeping.
JOURNAL OF AFFECTIVE DISORDERS
(2024)